Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in adults with IgA nephropathy
NL-OMON59653Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravulizumab in IgA nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Dec 2024; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON59653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59653.